squiffy2
10-15-2007, 09:44 AM
Betaferon® (interferon beta-1b) significantly delays the development of confirmed disability progression and the development of clinically definite multiple sclerosis (MS) in patients who are treated shortly after their first clinical MS event or “attack”.
The presence of neutralizing antibodies (NAbs) does not affect the efficacy of early Betaferon® treatment. (1) This is according to new evidence from the landmark BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) study presented today at the 23rd Congress of the European Committee for Treatment and Research in MS (ECTRIMS).
Neutralizing antibodies can develop in MS patients being treated with any of the currently available immunomodulatory therapies. However, there has been debate over whether or not such antibodies can affect a treatment’s efficacy..............
For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : BETASERON® (BETAFERON®) (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1766)
The presence of neutralizing antibodies (NAbs) does not affect the efficacy of early Betaferon® treatment. (1) This is according to new evidence from the landmark BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) study presented today at the 23rd Congress of the European Committee for Treatment and Research in MS (ECTRIMS).
Neutralizing antibodies can develop in MS patients being treated with any of the currently available immunomodulatory therapies. However, there has been debate over whether or not such antibodies can affect a treatment’s efficacy..............
For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : BETASERON® (BETAFERON®) (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1766)